Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo … RR Holman, RL Coleman, JCN Chan, JL Chiasson, H Feng, J Ge, ... The lancet Diabetes & endocrinology 5 (11), 877-886, 2017 | 321 | 2017 |
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin* U Graefe‐Mody, C Friedrich, A Port, A Ring, S Retlich, T Heise, A Halabi, ... Diabetes, Obesity and Metabolism 13 (10), 939-946, 2011 | 302 | 2011 |
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients T Heise, EU Graefe‐Mody, S Hüttner, A Ring, D Trommeshauser, KA Dugi Diabetes, Obesity and Metabolism 11 (8), 786-794, 2009 | 231 | 2009 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers S Hüttner, EU Graefe‐Mody, B Withopf, A Ring, KA Dugi The Journal of Clinical Pharmacology 48 (10), 1171-1178, 2008 | 204 | 2008 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and … JB Green, MA Bethel, SK Paul, A Ring, KD Kaufman, DR Shapiro, ... American heart journal 166 (6), 983-989. e7, 2013 | 178 | 2013 |
Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes T Forst, B Uhlig‐Laske, A Ring, U Graefe‐Mody, C Friedrich, K Herbach, ... Diabetic Medicine 27 (12), 1409-1419, 2010 | 176 | 2010 |
The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus T Forst, B Uhlig‐Laske, A Ring, A Ritzhaupt, U Graefe‐Mody, KA Dugi Diabetes, Obesity and Metabolism 13 (6), 542-550, 2011 | 121 | 2011 |
Pharmacokinetics of linagliptin in subjects with hepatic impairment U Graefe‐Mody, P Rose, S Retlich, A Ring, L Waldhauser, R Cinca, ... British journal of clinical pharmacology 74 (1), 75-85, 2012 | 110 | 2012 |
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects EU Graefe-Mody, S Padula, A Ring, B Withopf, KA Dugi Current medical research and opinion 25 (8), 1963-1972, 2009 | 90 | 2009 |
A randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and … DJ Bowrey, M Baker, V Halliday, AL Thomas, R Pulikottil-Jacob, K Smith, ... Trials 16, 1-12, 2015 | 83 | 2015 |
Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all … M Klueglich, A Ring, S Scheuerer, D Trommeshauser, C Schuijt, ... Journal of clinical pharmacology 45 (9), 1055-1062, 2005 | 83 | 2005 |
The Novel, Potent, and Selective DPP-IV Inhibitor BI 1356 Significantly Lowers HbA1c after only 4 Weeks of Treatment in Patients with Type 2 Diabetes. T Forst, B Uhlig-Laske, A Ring, A Ritzhaupt, U Graefe-Mody, KA Dugi Diabetes 56, 2007 | 63 | 2007 |
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus T Rauch, U Graefe-Mody, CF Deacon, A Ring, JJ Holst, HJ Woerle, ... Diabetes Therapy 3, 1-14, 2012 | 60 | 2012 |
BI 1356, a novel xanthine-based DPP-IV inhibitor, exhibits high potency with a wide therapeutic window and significantly reduces postprandial glucose excursions after an oGTT KA Dugi, T Heise, A Ring, U Graefe-Mody, A Ritzhaupt, S Huettner Diabetologia 50, S367-S367, 2007 | 60 | 2007 |
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study A Ring, T Brand, S Macha, K Breithaupt-Groegler, G Simons, B Walter, ... Cardiovascular diabetology 12, 1-11, 2013 | 55 | 2013 |
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg–10mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor … S Retlich, V Duval, A Ring, A Staab, S Hüttner, A Jungnik, U Jaehde, ... Clinical pharmacokinetics 49, 829-840, 2010 | 55 | 2010 |
Complete versus lesion-only primary PCI: the randomized cardiovascular MR CvLPRIT substudy GP McCann, JN Khan, JP Greenwood, S Nazir, M Dalby, N Curzen, ... Journal of the American College of Cardiology 66 (24), 2713-2724, 2015 | 52 | 2015 |
Complete versus lesion-only primary PCI: the randomized cardiovascular MR CvLPRIT substudy GP McCann, JN Khan, JP Greenwood, S Nazir, M Dalby, N Curzen, ... Journal of the American College of Cardiology 66 (24), 2713-2724, 2015 | 52 | 2015 |
Treatment with BI 1356, a Novel and Potent DPP-IV Inhibitor, Significantly Reduces Glucose Excursions after an oGTT in Patients with Type 2 Diabetes. T Heise, R Tiessen, S Huettner, A Ring, A Ritzhaupt, U Graefe-Mody, ... Diabetes 56, 2007 | 51 | 2007 |
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. U Graefe-Mody, S Huettner, H Stähle, A Ring, KA Dugi International journal of clinical pharmacology and therapeutics 48 (6), 367-374, 2010 | 49 | 2010 |